MCID: NSL008
MIFTS: 43

Nasal Cavity Cancer

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Nasal Cavity Cancer

MalaCards integrated aliases for Nasal Cavity Cancer:

Name: Nasal Cavity Cancer 12 15
Nasal Cavity Carcinoma 12 15 72
Malignant Neoplasm of Nasal Cavities 12
Malignant Tumor of the Nasal Cavity 12
Malignant Neoplasm of Nasal Cavity 72
Carcinoma of Nasal Cavity 12
Neoplasm of Nasal Cavity 72
Cancer of Nasal Cavity 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10811 DOID:4931
ICD9CM 35 160.0
NCIt 50 C4918 C9336
SNOMED-CT 68 93917007
ICD10 33 C30.0
UMLS 72 C0345630 C0728864 C1377785

Summaries for Nasal Cavity Cancer

Disease Ontology : 12 A nasal cavity cancer that has material basis in epithelial cells.

MalaCards based summary : Nasal Cavity Cancer, also known as nasal cavity carcinoma, is related to inverted papilloma and keratinizing squamous cell carcinoma, and has symptoms including pain and rhinorrhea. An important gene associated with Nasal Cavity Cancer is CXCL11 (C-X-C Motif Chemokine Ligand 11), and among its related pathways/superpathways are Gastric cancer and Human T-cell leukemia virus 1 infection. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and brain, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Nasal Cavity Cancer

Diseases in the Nasal Cavity Cancer family:

Nasal Cavity Carcinoma in Situ

Diseases related to Nasal Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Related Disease Score Top Affiliating Genes
1 inverted papilloma 30.6 TP53 KRT7 CDKN2A
2 keratinizing squamous cell carcinoma 30.6 TP53 KRT5 CDKN2A
3 epithelial-myoepithelial carcinoma 30.6 TP53 KRT7 HRAS
4 papilloma 30.3 TP53 KRT8 KRT7 KRT5 CDKN2A
5 adenocarcinoma 30.1 TP53 KRAS HRAS CDKN2A
6 transitional cell carcinoma 30.1 TP53 KRT8 KRT7 HRAS CDKN2A
7 adenoid cystic carcinoma 30.1 TP53 KRT7 KRT5 KRAS HRAS
8 nasal cavity adenocarcinoma 29.3 TP53 PDYN KRT7 KRAS HRAS GAST
9 nasal cavity squamous cell carcinoma 27.9 TIMP2 TIMP1 SLC25A19 NUTM1 MLANA KRT8
10 nasal cavity carcinoma in situ 12.6
11 nasal cavity cancer, childhood 12.5
12 proliferating trichilemmal cyst 10.7 KRT8 KRT7
13 ovary neuroendocrine neoplasm 10.7 KRT7 CDX2
14 endolymphatic sac tumor 10.7 KRT8 KRT7
15 ceruminoma 10.7 KRT7 KRT5
16 appendix adenocarcinoma 10.7 KRT7 CDX2
17 benign breast adenomyoepithelioma 10.7 KRT7 KRT5
18 anus adenocarcinoma 10.6 KRT7 CDX2
19 mucinous adenofibroma 10.6 KRT7 CDX2
20 calcifying epithelial odontogenic tumor 10.6 TP53 KRT8
21 vulvar intraepithelial neoplasia 10.6 TP53 KRT7
22 glandular cystitis 10.6 KRT7 CDX2
23 benign mesothelioma 10.6 KRT7 KRT5
24 vulva adenocarcinoma 10.6 KRT7 CDX2 CDKN2A
25 vulva squamous cell carcinoma 10.6 TP53 SERPINB3 CDKN2A
26 inverted transitional papilloma 10.6 KRT7 KRT5 CDKN2A
27 bladder carcinoma in situ 10.6 TP53 KRT7 CDKN2A
28 apocrine sweat gland neoplasm 10.6 KRT8 KRT7 KRT5
29 mucinous bronchioloalveolar adenocarcinoma 10.6 KRT7 CDX2 CDKN2A
30 pleomorphic carcinoma 10.6 TP53 KRT8 KRT7
31 glycogen-rich clear cell breast carcinoma 10.6 TP53 KRT7 CDKN2A
32 anal canal squamous cell carcinoma 10.6 SERPINB3 KRT5 CDKN2A
33 gastric tubular adenocarcinoma 10.6 KRT8 KRT7 CDX2
34 lymphoepithelioma-like carcinoma 10.6 KRT8 KRT7 KRT5
35 breast secretory carcinoma 10.6 KRT8 KRT7 KRT5
36 atypical choroid plexus papilloma 10.6 KRT8 KRT7 KRT5
37 malignant spiradenoma 10.6 TP53 KRT7 KRT5
38 pregnancy adenoma 10.6 KRT8 KRT7 KRT5
39 appendix cancer 10.5 TP53 KRT7 CDX2
40 cystic teratoma 10.5 TP53 KRT7 CDX2
41 olfactory neuroblastoma 10.5
42 middle ear carcinoma 10.5
43 teratoma 10.5 TP53 KRT7 CDX2
44 intraneural perineurioma 10.5 KRT8 KRT7 KRT5
45 pancreatic ductal carcinoma 10.5 TP53 KRT7 CDKN2A
46 eccrine sweat gland neoplasm 10.5 TP53 KRT7 KRT5
47 bladder adenocarcinoma 10.5 KRT7 HRAS CDX2
48 bladder squamous cell carcinoma 10.5 TP53 CDKN2A
49 optic nerve sheath meningioma 10.5 KRT5 CDKN2A
50 cystitis cystica 10.5 KRT7 KRT5 CDX2

Graphical network of the top 20 diseases related to Nasal Cavity Cancer:



Diseases related to Nasal Cavity Cancer

Symptoms & Phenotypes for Nasal Cavity Cancer

UMLS symptoms related to Nasal Cavity Cancer:


pain, rhinorrhea

MGI Mouse Phenotypes related to Nasal Cavity Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ANKRD11 CCK CDKN2A CDX2 GAST HRAS
2 growth/size/body region MP:0005378 10.15 ANKRD11 CDKN2A CDX2 FRS2 HRAS KRAS
3 digestive/alimentary MP:0005381 10.09 CDKN2A CDX2 GAST HRAS KRAS KRT5
4 embryo MP:0005380 10.01 ANKRD11 CDKN2A CDX2 FRS2 KRAS KRT8
5 neoplasm MP:0002006 9.8 CDKN2A CDX2 GAST HRAS KRAS TIMP1
6 no phenotypic analysis MP:0003012 9.76 CCK CDKN2A HRAS KRAS KRT5 MLANA
7 renal/urinary system MP:0005367 9.43 CCK HRAS KRAS KRT7 SLC25A19 TP53
8 skeleton MP:0005390 9.28 ANKRD11 CDKN2A CDX2 FRS2 HRAS KRAS

Drugs & Therapeutics for Nasal Cavity Cancer

Drugs for Nasal Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4 Liver Extracts Phase 4
5 Peripheral Nervous System Agents Phase 4
6 Neurotransmitter Agents Phase 4
7 Cholinergic Agents Phase 4
8 Nicotinic Agonists Phase 4
9 Central Nervous System Stimulants Phase 4
10 Autonomic Agents Phase 4
11 Antidepressive Agents Phase 4
12 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
13 Antidepressive Agents, Second-Generation Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Dopamine Agents Phase 4
16 Neurotransmitter Uptake Inhibitors Phase 4
17 Dopamine Uptake Inhibitors Phase 4
18 Psychotropic Drugs Phase 4
19
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
20
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
21 Muscarinic Agonists Phase 2, Phase 3
22
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
23
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
24
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
25
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
28
Fluorouracil Approved Phase 2 51-21-8 3385
29
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
30
Hydroxyurea Approved Phase 2 127-07-1 3657
31
Zinc Approved, Investigational Phase 2 7440-66-6 32051
32
Zinc oxide Approved Phase 2 1314-13-2
33
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
34
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
35 Cola Phase 2
36 Anti-Infective Agents Phase 2
37 Antiviral Agents Phase 1, Phase 2
38 HIV Protease Inhibitors Phase 2
39 Cytochrome P-450 CYP3A Inhibitors Phase 2
40
protease inhibitors Phase 2
41 Anti-Retroviral Agents Phase 2
42 Anti-HIV Agents Phase 2
43 Immunologic Factors Phase 2
44 Protective Agents Phase 2
45 Radiation-Protective Agents Phase 2
46 Immunosuppressive Agents Phase 2
47 Antimetabolites Phase 2
48 Antimetabolites, Antineoplastic Phase 2
49 Antineoplastic Agents, Phytogenic Phase 2
50 Tubulin Modulators Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
3 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
4 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
5 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
6 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
7 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
8 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
9 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
10 Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
11 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
12 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
13 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
14 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
15 A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation Completed NCT00534001 Phase 2 bupropion hydrochloride
16 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Head and Neck Terminated NCT00003489 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
17 A Phase I Study of Concomitant Chemoradiotherapy With Gemcitabine, Paclitaxel, and 5-FU for Patients With Advanced and/or Recurrent Cancer of the Head and Neck Unknown status NCT00004097 Phase 1 fluorouracil;gemcitabine hydrochloride;paclitaxel
18 Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors Completed NCT00978081 Phase 1 aminolevulinic acid hydrochloride
19 A Pharmacokinetic Study Evaluating the Safety, Tolerability and Maximally Tolerated Dose of 7-Day Continuous Infusions of L-778,123 in Patients With Recurrent of Refractory Solid Malignancies Completed NCT00003430 Phase 1 L-778,123
20 An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
21 A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas Terminated NCT00004261 Phase 1 EF5
22 Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
23 Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation Unknown status NCT01254591
24 PILOT STUDY OF THE CORRELATION BETWEEN THE FINDINGS OF ATYPICAL/MALIGNANT CELLS IN SPUTUM AND FLUORESCENCE BRONCHOSCOPY IN PATIENTS AT RISK FOR LUNG CANCER OF THE LIFE IMAGING SYSTEM AND WHITE LIGHT BRONCHOSCOPY Completed NCT00019201
25 Smoking Relapse Prevention Among Postpartum Women Completed NCT00310115
26 International Study of the Acceptability of Less Harmful Alternatives to Cigarettes (ISALHAC) - A Pilot Study Completed NCT00957424 nicotine replacement therapy
27 Neurocognitive Functioning in Adults With Upper Aerodigestive System Cancers Completed NCT00533884
28 Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers Completed NCT00790569 nicotine;varenicline
29 Biomarkers and Dysplastic Respiratory Epithelium Recruiting NCT00900419
30 A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer Recruiting NCT02589938
31 Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use Active, not recruiting NCT00799669
32 Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure Active, not recruiting NCT00530049
33 Electroacupuncture for Xerostomia in Head and Neck Patients Terminated NCT00623129
34 Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors Withdrawn NCT00499291 paclitaxel albumin-stabilized nanoparticle formulation

Search NIH Clinical Center for Nasal Cavity Cancer

Genetic Tests for Nasal Cavity Cancer

Anatomical Context for Nasal Cavity Cancer

MalaCards organs/tissues related to Nasal Cavity Cancer:

41
Lung, Breast, Brain, Liver, Prostate, Testes, Cervix

Publications for Nasal Cavity Cancer

Articles related to Nasal Cavity Cancer:

(show all 24)
# Title Authors PMID Year
1
Molecular characterization of cancers with NTRK gene fusions. 38
30171197 2019
2
Primary surgical treatment of nasal vestibule cancer - therapeutic outcome and reconstructive strategies. 38
30098234 2018
3
Nasal cavity reirradiation: a challenging case for comparison between proton therapy and volumetric modulated arc therapy. 38
26166226 2016
4
Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome. 38
27374712 2016
5
Conjunctival Melanoma on 18F-FDG PET/CT as a Second Primary Cancer. 38
26646997 2016
6
Health-related quality of life of head and neck cancer patients with successful oncological treatment. 38
24986429 2015
7
(P092) definitive chemoradiotherapy or radiotherapy for unresectable, very locally advanced, or medically inoperable paranasal sinus and nasal cavity cancer. 38
25930909 2015
8
Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. 38
20185459 2010
9
Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. 38
18705398 2008
10
Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. 38
17161557 2007
11
[Epidemiologic analysis of 72 carcinomas of the nasal cavity and paranasal sinuses]. 38
17117693 2006
12
Prognostic factors in maxillary sinus and nasal cavity carcinoma. 38
15923101 2005
13
Sulindac sulfide-induced apoptosis in sinonasal cancer cells. 38
15880954 2005
14
[Prognostic factors of 60 nasal cavity carcinoma patients]. 38
12667333 2002
15
Cancer of the nasal cavity: survival and factors influencing prognosis. 38
12220216 2002
16
[Radiation treatment in the carcinoma of paranasal sinuses and nasal cavity]. 38
9082829 1996
17
Carcinomas of the nasal cavity. 38
1410570 1992
18
Ethmoid and upper nasal cavity carcinoma: treatment, results and complications. 38
2123986 1990
19
Nasal obstruction portending nasal cavity cancer. 38
2599810 1989
20
Carcinoma of the nasal cavity--results of primary and adjuvant radiotherapy. 38
2846481 1988
21
Paranasal sinuses and nasal cavity cancer: different radiotherapeutic options, results and late damages. 38
3810867 1986
22
Descriptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses. 38
6996871 1980
23
[Immediate and late results of the treatment of nasal cavity cancer]. 38
636621 1978
24
[Wegener's disease and nasal cavity cancer]. 38
855456 1977

Variations for Nasal Cavity Cancer

Expression for Nasal Cavity Cancer

Search GEO for disease gene expression data for Nasal Cavity Cancer.

Pathways for Nasal Cavity Cancer

GO Terms for Nasal Cavity Cancer

Biological processes related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.43 TIMP1 SERPINB3 KRAS HRAS CDX2 CCK
2 replicative senescence GO:0090399 9.37 TP53 CDKN2A
3 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.32 TIMP2 TIMP1
4 response to isolation stress GO:0035900 9.26 KRAS HRAS
5 negative regulation of metallopeptidase activity GO:1905049 9.16 TIMP2 TIMP1
6 Ras protein signal transduction GO:0007265 8.92 TP53 KRAS HRAS CDKN2A

Molecular functions related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.92 TP53 TIMP2 TIMP1 SERPINB3

Sources for Nasal Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....